STATCenter·
STAT+: An AI biotech CEO sets the record straight on AI drug development hype
CEO of BigHat Biosciences, which designs antibody therapies using machine-learning, on how AI can, and cannot, help in drug development.
Read at STAT →
Health · 1 sources covering this
STAT+: An AI biotech CEO sets the record straight on AI drug development hype
CEO of BigHat Biosciences, which designs antibody therapies using machine-learning, on how AI can, and cannot, help in drug development.
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/736ccb4464e0a2ed87b5b16d12e10401d5f57aeb" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="STAT+: An AI biotech CEO sets the record straight on AI drug development hype"></iframe>
